Mechelen, Belgium; 19 December 2011 – Following warrant exercises during the exercise period from 28 November through 12 December 2011, Galapagos issued 1,575 new ordinary shares on 19 December 2011 for a total capital increase (including issuance premium) of €11,214.00. No member of the Board or Executive Committee exercised warrants.

To date, Galapagos’ total share capital amounts to €142,928,662.81; the total number of securities conferring voting rights is 26,421,441, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities which confer voting rights is 3,342,602, which is also the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing GLPG0634, as well as one of the largest pipelines in biotech, with seven programs in development and over 50 discovery programs. The Galapagos Group has about 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com